Shares of Dr. Reddy's Lab
slipped 1% in the afternoon session after US health regulator USFDA issued a Form-483 with 5 observations.
The company said in its filing that the audit of its API manufacturing plant 2 at Bollaram, Hyderabad by the USFDA, has been completed with 5 observations.
"We will address them (observations) comprehensively within the stipulated timeline,” the company stated.
Dr Reddys Laboratories Ltd is currently trading at Rs2,632, down by Rs20.15 or 0.76% from its previous closing of Rs2,652.15 on the BSE.
The scrip opened at Rs2,654.95 and has touched a high and low of Rs2,660 and Rs2,587.35 respectively.